Precigen (NASDAQ:PGEN – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, March 19th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $1.30 million for the quarter.
Precigen Stock Performance
Shares of NASDAQ:PGEN opened at $1.78 on Tuesday. The company has a 50 day moving average price of $1.56 and a two-hundred day moving average price of $1.13. The company has a market capitalization of $521.31 million, a PE ratio of -3.24 and a beta of 1.58. Precigen has a 52 week low of $0.65 and a 52 week high of $2.17.
Analyst Ratings Changes
Several brokerages recently commented on PGEN. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective (up previously from $4.00) on shares of Precigen in a research note on Thursday, January 23rd. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price target on shares of Precigen in a research report on Tuesday, January 14th. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Precigen currently has an average rating of “Hold” and a consensus price target of $7.00.
About Precigen
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
Recommended Stories
- Five stocks we like better than Precigen
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Can TikTok Stock Picks Really Make You Rich?
- Earnings Per Share Calculator: How to Calculate EPS
- The “Quality” Rotation: Back to Basics Investing
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.